It’s been a hot M&A market for biotech companies developing treatments for rare diseases. Nevetheless, Corbus Pharmaceuticals CEO Dr. Yuval Cohen says he is more focused on developing his cystic fibrosis drug Resunab than on deal-making. 'We can certainly choose to partner with a large pharmaceutical company or we can also do it on our own,' says Cohen. 'We have a small, but experienced and nimble team with the resources to take the drug all the way to market.' Resunab is an orally bioavailable synthetic small-molecule designed to naturally switch off heightened inflammation and restore the system to its normal level. The Resunab IND application was approved by the FDA in May and the company is initiating a Phase 2 clinical study for cystic fibrosis which it hopes to begin later this year. Mirroring the volatility in the biotech market this year, shares of the micro-cap company Corbus traded around $3 at last check, up from $2 in February but down from $4 just two weeks ago.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.